Unity Biotechnology (NASDAQ:UBX) Stock Rating Upgraded by Wedbush

Wedbush upgraded shares of Unity Biotechnology (NASDAQ:UBX – Free Report) from a neutral rating to an outperform rating in a research note released on Thursday morning, Marketbeat Ratings reports. The firm currently has $4.00 target price on the stock. Separately, HC Wainwright reaffirmed a buy rating and issued a $10.00 price target on shares of […]

Related Keywords

,Acadian Asset Management ,Geode Capital Management ,Vanguard Group Inc ,Unity Biotechnology Inc ,Nasdaq ,Unity Biotechnology Company Profile ,Renaissance Technologies ,Unity Biotechnology ,Free Report ,Marketbeat Ratings ,Biotechnology Stock Down ,Asset Management ,Street Corp ,Capital Management ,Get Free Report ,Unity Biotechnology Daily ,Nasdaq Ubx ,Subx ,Medical ,Upgrade ,Wedbush ,